Patient enrollment has begun in trials of SkinTE human cellular and tissue skin-repair product for diabetic foot ulcers and venous leg ulcers, the Salt Lake City company announced April 1.

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in September 2017.